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Abstract: Zinc-binding protein-89 (ZBP-89; ZNF148, BERF-1, BFCOL-1) is a zinc-finger 
transcription factor of the Kruppel family. It has been shown to regulate the expression of 
a number of genes, acting as either an activator or repressor of gene expression, depending 
on the context. It is over-expressed in several cancers, but has been shown to be involved in 
apoptosis and to have a negative influence on cell growth in part by interactions with p53. 
Previously, ZBP-89 was shown to activate transcription of the matrix metalloproteinase-3 
(MMP-3) gene by binding to a polymorphic promoter element in competition with nuclear 
factor κB (NF-κB). NF-κB is known to be a key regulator of the inflammatory response, but 
relatively little is known about regulation of ZBP-89. In order to ascertain whether ZBP-89 
is regulated during inflammation, we designed experiments to determine whether and to what 
extent ZBP-89 levels are affected by inflammatory cytokines. Here we show that ZBP-89 mRNA 
and protein expression are significantly inhibited in human fibroblasts by the inflammatory 
cytokine interleukin-1β. Since any change in the levels of ZBP-89 would presumably impact 
the regulation of MMP-3 and other ZBP-89 target genes, these results provide important insight 
into mechanisms involved in fine-tuning the immune response.
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Introduction
Zinc-binding protein-89 (ZBP-89; ZNF148, BERF-1, BFCOL-1) is a ubiquitously 
expressed zinc-finger transcription factor of the Krüppel family. It has been shown 
to regulate the expression of a number of genes, acting as either an activator1–4 or 
repressor5–10 of transcription, depending on the context. When ZBP-89 is a repressor 
of gene expression, it often accomplishes this by competing for an overlapping 
binding site with another transcription factor, usually Sp1,5,7,11 although the protein 
does also have a repression domain.8
The case of human matrix metalloproteinase 3 (MMP-3) is somewhat different, 
however, in that ZBP-89 has been shown to activate transcription in competition 
with NF-κB for binding to a polymorphic 5T/6T site in the promoter.4,12 This site 
was originally identified as a repressor element, with the 6T version being a more 
effective repressor than the 5T in transiently transfected fibroblasts.13 In COS-1 cells, 
over-expressed ZBP-89 activated the 5T promoter more efficiently than the 6T, while 
NF-κB repressed both.12 This polymorphism is functionally significant in that it has 
been shown both to influence levels of MMP-3 in tissues14,15 and to be associated 
with increased risk or severity of several disease states.16–19 For example, individuals 
homozygous for the 6T site have been shown to express less MMP-3 protein in aortic 
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wall and dermal tissues and to have more rapid progression 
of atherosclerosis,14,15,18,19 while individuals homozygous for 
the 5T site express more protein in tissues and are at increased 
risk for myocardial infarctions and aneurysms.16,17,20
Since the role of the polymorphism in determining the 
levels of MMP-3 protein expression likely depends on 
the relative concentrations of NF-κB and ZBP-89 under 
various conditions, it is important to understand how each is 
regulated. While NF-κB is the prototypical pro-inflammatory 
response factor, responsible for coordinating the induction of 
a variety of genes in response to pro-inflammatory cytokines, 
relatively little is known about regulation of ZBP-89. Here we 
show that ZBP-89 mRNA and protein levels are decreased 
by inflammatory cytokines IL-1β and TNF-α in human 
gingival fibroblasts isolated from patients with periodontitis, 
and by IL-1β and lipopolysaccharide (LPS) in WI-38 normal 
human diploid fibroblasts. Interestingly, TNF fails to inhibit 
ZBP-89 expression in WI-38 cells, suggesting some cell 
type specificity in the regulation of ZBP-89.
Materials and methods
Cell culture
Human gingival tissue from patients undergoing periodontal 
surgery was obtained from Newtown Dental Associates 
in Newtown, PA. The tissue was processed by enzymatic 
dispersion to produce primary fibroblast cultures (HGF). 
Cells were maintained in Eagle’s minimal essential 
medium (EMEM) supplemented with 10% fetal bovine 
serum and antibiotic/antimycotic (penicillin, streptomycin, 
amphotericin; Gibco BRL/Invitrogen, Carlsbad, CA, USA). 
Cells between passages 3 and 5 were used for experiments. 
WI-38 cells were obtained from ATCC (Manassas, VA, 
USA) and maintained as suggested.
RnA isolation and real-time polymerase 
chain reaction
Cells were serum-deprived for 16 hours in serum-free 
EMEM supplemented with 10% ITS (insulin, transferrin, 
sodium selenite; Sigma-Aldrich, St. Louis, MO, USA) 
prior to the addition of the indicated doses of cytokines. 
IL-1β was obtained from DuPont-Merck Corp (Wilmington, 
DE, USA), IL-4 from Promega (Madison, WI, USA), 
and TNFα from Sigma-Aldrich. LPS was obtained from 
Calbiochem (San Diego, CA) and epidermal growth factor 
(EGF) from Biosource International, (Camarillo, CA, 
USA). Total RNA was isolated at the indicated times using 
the RNAqueous-4PCR kit (Ambion/Applied Biosystems, 
Austin, TX, USA) according to manufacturer’s instructions 
and reverse transcribed into cDNA using the High Capacity 
cDNA Archive Kit (Applied Biosystems) and Thermal 
Cycler Genius. Real-time polymerase chain reactions (PCR) 
consisted of 2 µl of cDNA, 6.8 µl of H
2
O, 10 µl of the 
Premix Ex Taq™ (master mix and 0.4 µl ROX Reference 
Dye; TAKARA, Madison, WI, USA) and 0.8 µl probes 
(ZNF148, glyceraldehyde-3-phosphate dehydrogenase 
[GAPDH]; Applied Biosystems). Real-time PCR analysis 
was done using the Applied Biosystem 7500 Real Time PCR 
system. Reactions were done in triplicate and results were 
normalized to GAPDH.
Protein isolation and Western blotting
Whole cell extracts were prepared using the Nuclear 
Extraction Kit from Active Motif (Carlsbad, CA, USA) 
using the suggested procedure for whole cell extraction, 
and quantified in mini-Bradford assays (Pierce Biotech, 
Rockford, IL, USA). Thirty µg extract were separated on 
10% SDS-polyacrylamide gels. Proteins were transferred 
to Immobilon-P Transfer Membrane (Millipore, Billerica, 
MA, USA) and the membrane was blocked overnight with 
Super Block blocking buffer (Pierce Biotech). The blot was 
then incubated with anti-ZBP-89 (Santa Cruz, Santa Cruz, 
CA, USA) antibody diluted 1:1000 in Super Block for 
one hour at room temperature. After washing three times 
in TBST (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% 
Tween 20), the blots were incubated with a donkey anti-goat 
(for ZBP-89) secondary antibody conjugated to horseradish 
peroxidase (Pierce Biotech) for one hour. After three more 
washes in TBST, the blot was incubated with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce Biotech) and 
exposed to X-ray film.
Results
Human gingival fibroblasts (HGF) were serum-deprived for 
16 hours and then treated with IL-1 (10 ng/ml) and/or IL-4 
(10 ng/ml) for 12 hours. ZBP-89 mRNA was measured by 
real-time PCR. Figure 1 shows a decrease in steady-state 
levels of ZBP-89 mRNA in response to the pro-inflammatory 
cytokine IL-1β, but no change in response to the anti-
inflammatory IL-4. Tumor necrosis factor-α (TNF-α) also 
inhibits ZBP-89 expression in HGF to a similar extent, and 
both inflammatory cytokines are effective at doses as low as 
0.1 ng/ml (Figure 2). A time course shows that both mRNA 
and protein expression are inhibited within six hours of 
treatment with IL-1β, and the levels continue to decrease for 
at least 24 hours (Figure 3).
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Since there have been some reports of altered responses 
in f ibroblasts isolated from individuals with chronic 
inflammatory conditions, WI-38 normal human fibroblasts 
were used to compare responses. Our results (Figure 4) 
demonstrate a similar decrease in response to IL-1β, no change 
in response to IL-4, transforming growth factor-β (TGF-β), 
or EGF. LPS, however, did inhibit ZBP-89 expression, 
though not as much as IL-1β. Interestingly, TNF did not 
inhibit ZBP-89 mRNA expression in these normal cells.
Discussion
Here we report that the expression of ZBP-89 is inhibited by 
inflammatory cytokines IL-1β and TNF-α in human gingival 
fibroblasts isolated from patients with severe periodontitis, 
and by IL-1β and LPS but not TNF-α in WI-38 normal 
human fibroblasts.
The mechanism of cytokine suppression of ZBP-89 
mRNA levels was not determined. Since both mRNA and 
protein levels were significantly reduced within six hours, 
it is possible that there is a direct effect on transcription. 
However, changes in mRNA stability cannot be ruled out. 
Sequence analysis21 identified several putative transcription 
factor binding sites that were well conserved in the promoters 
of the mouse and human genes, including Sp1, TCF-1, 
Oct1, NF-κB, MyoD, Ets1 LyF-1, and BERF-1/ZBP-89 
itself, but a functional analysis of these elements has not 
been done. There was evidence of alternative polyadenyl-
ation sites in the 3′ untranslated region,21 but no AUUA 
elements associated with mRNA instability have been noted. 
In addition to regulation of the levels of ZBP-89 expressed, 
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Figure 1 IL-1 inhibits ZBP-89 mRnA expression in hgF. hgF cultures were 
serum-deprived for 16 hours prior to addition of IL-1β (10 ng/ml) and/or IL-4 
(10 ng/ml).  Total RnA was harvested 12 hours after cytokine treatment, quantitated 
by real-time PCR and normalized to levels of gAPDh.
Notes:  The graph represents data from seven independent experiments performed 
in triplicate, expressed as mean ± SEM. Statistical significance was determined using 
student’s t-test. **p  0.01.
Abbreviations: gAPDh, glyceraldehyde-3-phosphate dehydrogenase; hgF, human 
gingival fibroblasts; IL, interleukin; PCR, polymerase chain reaction; SEM, standard 
error of mean.
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Figure 2 IL-1β and TnF-α inhibit ZBP-89 mRnA expression at low doses. hgF cultures were serum-deprived for 16 hours prior to addition of IL-1β (10 ng/ml) or TnF-α 
(10 ng/ml).  Total RnA was harvested 12 hours after cytokine treatment, quantitated by real-time PCR and normalized to levels of gAPDh.
Notes:  The graph represents data from five independent experiments performed in triplicate, expressed as mean ± SEM. Statistical significance was determined using Student’s 
t-test. **p  0.01.
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HGF, human gingival fibroblasts; IL, interleukin; PCR, polymerase chain reaction; SEM, standard error of 
mean;  TnF, tumor necrosis factor.
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Figure 3 IL-1β inhibits ZBP-89 mRnA expression within six hours. A) hgF cultures were serum-deprived for 16 hours prior to addition of IL-1β (10 ng/ml). Total RnA was 
harvested at the indicated hours after cytokine treatment, quantitated by real-time PCR and normalized to levels of gAPDh. B) Immunoblot of whole cell extracts isolated 
from hgF cultures treated for the indicated times with IL-1β as described above and treated anti-ZBP-89 antibody.
Notes:  The graph represents data from five independent experiments performed in triplicate, expressed as mean ± SEM. Statistical significance was determined using Student’s 
t-test. *p  0.05.
Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HGF, human gingival fibroblasts; IL, interleukin; PCR, polymerase chain reaction; SEM, standard error 
of mean.
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Figure 4  ZBP-89 mRnA is inhibited by IL-1β and LPs, but not by  TnF-α in  WI-38 cells.   WI-38 cell cultures were serum-deprived for 16 hours prior to addition of cytokines/
inflammatory mediator (10 ng/ml).   Total RNA was harvested 12 hours after treatment, quantitated by real-time PCR, and normalized to levels of GAPDH.
Notes:   The graph represents data from two independent experiments performed in triplicate, expressed as mean ± seM.
Abbreviations: gAPDh, glyceraldehyde-3-phosphate dehydrogenase; egF, epidermal growth factor; IL, interleukin; LPs, lipopolysaccharide; PCR, polymerase chain reaction; 
TnF, tumor necrosis factor; seM, standard error of mean.
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there is also evidence of post-translational regulation of 
ZBP-89 transcriptional activity by phosphorylation22 and/or 
sumoylation,23 but so far little is known about what kinds 
of stimuli might regulate these modifications, and in what 
cellular contexts.
Although ZBP-89 is ubiquitously expressed, it is more 
abundant in some tissues6,24,25 and there is evidence of 
developmental regulation of its expression.8 In addition, 
its mRNA has been shown to be modestly induced by 
retinoic acid26 as well as TGF-β and butyrate.1,27 Although 
it has been shown to be over-expressed in certain cancers,28 
it limits cell proliferation, in part through interactions with 
p53,29 and appears to have roles in cell differentiation8,30 and 
apoptosis.31 In addition, ZBP-89 has also been proposed to 
have a protective effect in the resolution of inflammation.32 
Therefore, one might speculate that suppression of 
ZBP-89 expression by inflammatory cytokines might 
serve to allow cytokine mediated increases in cellular 
proliferation, prolong the immune response and/or protect 
against apoptosis. For example, both IL-1 and TNF have 
been shown to stimulate ornithine decarboxylase (ODC) 
expression, but only in cell types in which they are able 
to stimulate proliferation.33 It is tempting to speculate that 
they might do this, at least in part, by inhibiting ZBP-89 
repression of ODC expression. On the MMP-3 promoter, 
decreased levels of  ZBP-89 would presumably allow 
NF-κB to bind unopposed to both the 5T and 6T versions of 
the polymorphic site, causing both to function as repressor 
elements in vivo (although the 6T would be a more effective 
repressor element because of a higher affinity for NF-κB). 
This would help to limit the amount of MMP-3 expressed, 
and thus reduce pathological tissue remodeling during 
prolonged inflammation.
It is interesting to note that although TNF-α inhibited 
ZBP-89 mRNA expression in HGF in a way similar to 
IL-1β, it failed to do so in WI-38 cells. This suggests that 
there are cell-type specific differences in the TNF-α path-
way as it relates to ZBP-89 expression. It is possible that 
these differences result from alterations in the HGF caused 
by chronic inflammation. For example, Rowanpura and 
colleagues34 showed that HGF isolated from patients with 
severe periodontitis differed from normal gingival fibroblasts 
from healthy donors in their response to prostaglandin E
2
, and 
that this was a result of a change in receptors from EP
2
 and 
EP
4
 in healthy tissue to predominantly EP
1
 in diseased tissue. 
In another study, TNF-α induced proliferation of synovial 
fibroblasts isolated from patients with rheumatoid arthritis, 
but failed to do so in normal synovial fibroblasts.35
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